» Articles » PMID: 9236543

A Molecular and Cellular Theory of Depression

Overview
Specialty Psychiatry
Date 1997 Jul 1
PMID 9236543
Citations 502
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have begun to characterize the actions of stress and antidepressant treatments beyond the neurotransmitter and receptor level. This work has demonstrated that long-term antidepressant treatments result in the sustained activation of the cyclic adenosine 3',5'-monophosphate system in specific brain regions, including the increased function and expression of the transcription factor cyclic adenosine monophosphate response element-binding protein. The activated cyclic adenosine 3',5'-monophosphate system leads to the regulation of specific target genes, including the increased expression of brain-derived neurotrophic factor in certain populations of neurons in the hippocampus and cerebral cortex. The importance of these changes is highlighted by the discovery that stress can decrease the expression of brain-derived neurotrophic factor and lead to atrophy of these same populations of stress-vulnerable hippocampal neurons. The possibility that the decreased size and impaired function of these neurons may be involved in depression is supported by recent clinical imaging studies, which demonstrate a decreased volume of certain brain structures. These findings constitute the framework for an updated molecular and cellular hypothesis of depression, which posits that stress-induced vulnerability and the therapeutic action of antidepressant treatments occur via intracellular mechanisms that decrease or increase, respectively, neurotrophic factors necessary for the survival and function of particular neurons. This hypothesis also explains how stress and other types of neuronal insult can lead to depression in vulnerable individuals and it outlines novel targets for the rational design of fundamentally new therapeutic agents.

Citing Articles

Mechanism of Wuling powder modulating proBDNF/p75NTR/sortilin and BDNF/TrkB pathways in the treatment of ulcerative colitis complicated with depression.

Wang J, Fan Y, Cao W, Huang R, Yao X, Li M World J Gastroenterol. 2025; 31(8):100227.

PMID: 40062332 PMC: 11886523. DOI: 10.3748/wjg.v31.i8.100227.


Serum BDNF Increase After 9-Month Contemplative Mental Training Is Associated With Decreased Cortisol Secretion and Increased Dentate Gyrus Volume: Evidence From a Randomized Clinical Trial.

Puhlmann L, Vrticka P, Linz R, Valk S, Papassotiriou I, Chrousos G Biol Psychiatry Glob Open Sci. 2025; 5(2):100414.

PMID: 39896238 PMC: 11786774. DOI: 10.1016/j.bpsgos.2024.100414.


Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today.

Radin D, Lippa A, Rana S, Fuller D, Smith J, Cerne R Pharmacol Biochem Behav. 2025; 248:173967.

PMID: 39894310 PMC: 11849398. DOI: 10.1016/j.pbb.2025.173967.


Beyond NMDA Receptors: A Narrative Review of Ketamine's Rapid and Multifaceted Mechanisms in Depression Treatment.

Antos Z, Zukow X, Bursztynowicz L, Jakubow P Int J Mol Sci. 2025; 25(24.

PMID: 39769420 PMC: 11728282. DOI: 10.3390/ijms252413658.


Neuroplasticity and Mechanisms of Action of Acute and Chronic Treatment with Antidepressants in Preclinical Studies.

Rosas-Sanchez G, German-Ponciano L, Guillen-Ruiz G, Cueto-Escobedo J, Limon-Vazquez A, Rodriguez-Landa J Biomedicines. 2025; 12(12.

PMID: 39767650 PMC: 11727250. DOI: 10.3390/biomedicines12122744.